Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Maike Marleen Holtsche; Nina Van Beek; Takashi Hashimoto; Giovanni Di Zenzo; Detlef Zillikens; Catherine Prost-Squarcioni; Matthias Titeux; Alain Hovnanian; Enno Schmidt; Stephanie Goletz

doi:10.2340/00015555-3774

Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Maike Marleen Holtsche, Nina Van Beek, Takashi Hashimoto, Giovanni Di Zenzo, Detlef Zillikens, Catherine Prost-Squarcioni, Matthias Titeux, Alain Hovnanian, Enno Schmidt, Stephanie Goletz^*

^*Corresponding author for this work

11 Citations (Scopus)

Abstract

Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

Original language	English
Article number	adv00420
Journal	Acta Dermato-Venereologica
Volume	101
Issue number	3
Pages (from-to)	adv00420
ISSN	0001-5555
DOIs	https://doi.org/10.2340/00015555-3774
Publication status	Published - 2021

Funding

This work was supported by grants from the Deutsche Forschungsgemeinschaft through CRU 303 Pemphigoid Diseases and Excellence Cluster Precision Medicine in Chronic Inflammation (EXC 2167). Type VII collagen NC1/2 ELISA (MBL, Nagoya, Japan) was purchased for a reduced price, type VII collagen NC1 ELISA and BIOCHIP® (Euroimmun, Lübeck, Germany) were provided free of charge. The authors thank Sarah Gaugel, L?beck, and Pierre Bonnesoeur, Paris, for excellent technical assistance. IDI-IRCCS and the Department of Dermatology, University of L?beck, are healthcare providers of the European Reference Network (ERN)-Skin. This work was supported by grants from the Deutsche Forschungsgemeinschaft through CRU 303 Pemphigoid Diseases and Excellence Cluster Precision Medicine in Chronic Inflammation (EXC 2167). Type VII collagen NC1/2 ELISA (MBL, Nagoya, Japan) was purchased for a reduced price, type VII collagen NC1 ELISA and BIOCHIP? (Euroimmun, L?beck, Germany) were provided free of charge. DZ and ES have a scientific cooperation with Euroimmun. The other authors have declared no conflicts of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 6 Clean Water and Sanitation

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Centers: Center for Research on Inflammation of the Skin (CRIS)

DFG Research Classification Scheme

2.21-05 Immunology
2.22-19 Dermatology

Access to Document

10.2340/00015555-3774

Cite this

Holtsche, M. M., Van Beek, N., Hashimoto, T., Di Zenzo, G., Zillikens, D., Prost-Squarcioni, C., Titeux, M., Hovnanian, A., Schmidt, E., & Goletz, S. (2021). Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity. Acta Dermato-Venereologica, 101(3), adv00420. Article adv00420. https://doi.org/10.2340/00015555-3774

@article{50a11e6ce627442ab4066d0b00e5285e,

title = "Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity",

abstract = "Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, L{\"u}beck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP{\textregistered}; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1\% and specificity of 100\%, followed by NC1 BIOCHIP{\textregistered} (sensitivity, 89.1\%; specificity, 100\%), immunoblotting with human dermis (sensitivity, 87.1\%; specificity 100\%), NC1-ELISA (sensitivity 82.2\%; specificity 98.6\%), NC1/NC2 ELISA (sensitivity 88.1\%; specificity 93.3\%), and full-length type VII collagen ELISA (sensitivity 80.2\%; specificity 93.8\%).",

author = "Holtsche, \{Maike Marleen\} and \{Van Beek\}, Nina and Takashi Hashimoto and \{Di Zenzo\}, Giovanni and Detlef Zillikens and Catherine Prost-Squarcioni and Matthias Titeux and Alain Hovnanian and Enno Schmidt and Stephanie Goletz",

year = "2021",

doi = "10.2340/00015555-3774",

language = "English",

volume = "101",

pages = "adv00420",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Medical Journals Sweden AB",

number = "3",

}

Holtsche, MM , Van Beek, N, Hashimoto, T, Di Zenzo, G, Zillikens, D, Prost-Squarcioni, C, Titeux, M, Hovnanian, A, Schmidt, E & Goletz, S 2021, 'Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity', Acta Dermato-Venereologica, vol. 101, no. 3, adv00420, pp. adv00420. https://doi.org/10.2340/00015555-3774

TY - JOUR

T1 - Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

AU - Holtsche, Maike Marleen

AU - Van Beek, Nina

AU - Hashimoto, Takashi

AU - Di Zenzo, Giovanni

AU - Zillikens, Detlef

AU - Prost-Squarcioni, Catherine

AU - Titeux, Matthias

AU - Hovnanian, Alain

AU - Schmidt, Enno

AU - Goletz, Stephanie

PY - 2021

Y1 - 2021

N2 - Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

AB - Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

UR - https://www.scopus.com/pages/publications/85103130698

U2 - 10.2340/00015555-3774

DO - 10.2340/00015555-3774

M3 - Journal articles

C2 - 33686442

AN - SCOPUS:85103130698

SN - 0001-5555

VL - 101

SP - adv00420

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 3

M1 - adv00420

ER -

Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Abstract

Funding

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Fingerprint

EXC 2167: Precision Medicine in Chronic Inflammation (PMI)

Cite this

Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Abstract

Funding

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Fingerprint

Projects

EXC 2167: Precision Medicine in Chronic Inflammation (PMI)

Cite this